title: Hematopoietic SCT in Europe: data and trends in 2011.
abstract: In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.
authors.affiliation: EBMT Activity Survey Office, Division of Hematology, Department of Medicine, University Hospital, Basel, Switzerland.
authors.forename: J R
authors.initials: JR
authors.lastname: Passweg
authors.forename: H
authors.initials: H
authors.lastname: Baldomero
authors.forename: M
authors.initials: M
authors.lastname: Bregni
authors.forename: S
authors.initials: S
authors.lastname: Cesaro
authors.forename: P
authors.initials: P
authors.lastname: Dreger
authors.forename: R F
authors.initials: RF
authors.lastname: Duarte
authors.forename: J H F
authors.initials: JH
authors.lastname: Falkenburg
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: D
authors.initials: D
authors.lastname: Farge-Bancel
authors.forename: H Bobby
authors.initials: HB
authors.lastname: Gaspar
authors.forename: J
authors.initials: J
authors.lastname: Marsh
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: C
authors.initials: C
authors.lastname: Peters
authors.forename: A
authors.initials: A
authors.lastname: Sureda
authors.forename: A
authors.initials: A
authors.lastname: Velardi
authors.forename: C
authors.initials: C
authors.lastname: Ruiz de Elvira
authors.forename: A
authors.initials: A
authors.lastname: Madrigal
mesh_terms: D005060:Europe; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data* / Q000639:trends*; D049674:History, 21st Century; D006801:Humans; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous